Medicines For Europe Finds Inequitable Essential Medicines Access In CEE Countries
Off-Patent Drugs Are Failing To Reach Their Full Potential Across The Region
Countries across Central and Eastern Europe are failing to reap the full benefit of generic and biosimilar competition, according to a new report from Medicines for Europe.
You may also be interested in...
Generic and biosimilar medicines must become central to European healthcare policy as the region looks to rebuild in the wake of the COVID-19 pandemic, Medicines for Europe’s new president, Rebecca Guntern of Sandoz, tells Generics Bulletin in an exclusive interview.
After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.
Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.